Knowthestock.com
CORT - Corcept Therapeutics Inc
Compare

Buy

Strong Growth and Improving●Stock Price Attractive

91%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 15.46%
Operating Income Growth is 14.87%
Net Income Growth is 12.56%
Earnings Per Share (EPS) Growth is 10.39%
Net Margin is 29.96%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 10.07
Debt Ratio is 0.08
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is STRONG
Cash from Operations Growth is 11.65%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Corcept Therapeutics Inc (CORT) - http://www.corcept.com/
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
Exchange - NASDAQ CAPITAL MARKET
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Joseph Belanoff
    Close
Cookie Policy
Disclaimer
Privacy Policy
Terms of Service
About Us
Contact Us
Help
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.